Bill & Melinda Gates Foundation

Likarda is a biotechnology company focused on developing innovative cell therapies and delivery technologies. Utilizing its patented Core-Shell Spherification® platform, Likarda specializes in cell encapsulation within biocompatible hydrogels, such as Hyaluronic Acid and PEG, which allows for customized delivery solutions tailored to the unique specifications of various cell therapies. The company's approach enables the creation of microcapsules that can provide injectable treatments with enhanced localization and efficacy or offer immunoprotective barriers for long-term cell transplants. Likarda is actively working on therapies for diabetes and osteoarthritis, including the delivery of islet-like cells for diabetes treatment and the slow-release injection of encapsulated stem cells for alleviating joint pain and reversing osteoarthritis degradation. The company has achieved significant recognition, including being named one of the "50 Most Promising Start-Ups in the World." To date, Likarda has secured over $8 million in funding through private investments, grants, and contract services.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

VitriVax is a biotechnology startup based in Boulder, Colorado, focused on developing an innovative vaccine formulation platform. The company utilizes its proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology to create vaccines that are more effective, affordable, and accessible worldwide. This technology addresses the challenges associated with vaccine stability and administration by enabling the development of thermostable, single-shot vaccines that can effectively incorporate both prime and booster doses. VitriVax's advancements in vaccine formulation aim to eliminate barriers to global vaccination, ultimately enhancing immune responses for a broad range of medical indications. The company has received significant funding, including over $5 million from various sources such as the National Institutes of Health, the National Science Foundation, and the Bill and Melinda Gates Foundation, to support its mission.

BioSurfaces is a developer of medical devices specializing in tissue engineering and personal care products. The company leverages advanced electrospinning technology to produce nanofibrous materials that facilitate controlled drug delivery and enhance healing at the implant site. By utilizing a room-temperature electrospinning process, BioSurfaces enables the integration of drug loading within each fiber, creating a reservoir for sustained drug release. This innovative approach allows for the creation of devices and coatings as thin as 10 micrometers, making it possible to treat diseases directly at the site of implantation. The company aims to provide next-generation solutions for the medical and personal care markets, focusing on improving patient outcomes through effective disease treatment and tissue regeneration.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

La Ruche Health provides an innovative platform that connects patients with virtual and at-home healthcare services. Utilizing health AI technology, it offers advice and facilitates the booking of medical services and lab tests through user-friendly applications on iOS, Android, and WhatsApp. The company has recognized WhatsApp as a key distribution channel, being the first to integrate generative AI into this platform to enhance conversational experiences, particularly for low-literacy communities. Additionally, La Ruche Health develops a medical record management system that enables healthcare teams to efficiently manage and exchange medical data through both web and mobile applications. This comprehensive platform allows for virtual and physical consultations, as well as access to a wellness marketplace designed to make modern health services more affordable and accessible to various communities.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Eyam Vaccines and Immunotherapeutics is a life science company focused on the research and development of vaccines aimed at combating infectious diseases. The company specializes in creating vaccines that target the spike glycoprotein protein, which generates neutralizing antibodies against the novel coronavirus. Eyam utilizes a self-amplifying vaccine platform designed to produce low-dose vaccines that offer advanced targeting capabilities for broad coverage and protection, addressing both current and emerging variants. By prioritizing the development of innovative vaccine solutions, Eyam aims to meet critical healthcare needs in the face of evolving infectious threats.

Field develops technology aimed at enhancing pharmaceutical supply chains, enabling governments and businesses to deliver healthcare more effectively in rapidly growing regions. The company's platform focuses on digitizing and modernizing supply chain processes, making them easier to use and more scalable. By partnering with communities, Field aims to strengthen and sustain these vital supply chains, ultimately improving access to healthcare for millions of people globally.

Immorna is a biotechnology company focused on developing RNA-based therapeutics and vaccines. The company employs various RNA platforms, including conventional, self-replicating, and circular RNA, to create innovative treatments. Immorna has established a comprehensive central management console for RNA synthesis, purification, and analytical testing, which facilitates both clinical and commercial development. Additionally, the company has developed advanced screening tools and a range of RNA delivery vehicles, such as polymers and lipid nanoparticles, incorporating proprietary ionizable cationic lipids. This robust infrastructure positions Immorna to contribute significantly to the field of RNA therapeutics.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite combines advanced high-throughput experimental and computational methods to create tailored delivery vehicles. These vehicles are designed to effectively transport a wide range of genetic materials with specific targeting capabilities, facilitating research in functional chemistry and enhancing the design of therapeutically relevant gene delivery systems.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds (VOCs) in breath, serving as biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA, disease biomarker detection tools such as Lonestar, and advanced mass spectrometry solutions like UltraFAIMS. These products are employed in the diagnosis and monitoring of conditions like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced chemical detection. Through its subsidiary, Owlstone Medical, the company aims to lead the global market in non-invasive diagnostics for cancer, infectious, and inflammatory diseases, with a focus on breath-based diagnostic tools.

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds (VOCs) in breath, serving as biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA, disease biomarker detection tools such as Lonestar, and advanced mass spectrometry solutions like UltraFAIMS. These products are employed in the diagnosis and monitoring of conditions like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced chemical detection. Through its subsidiary, Owlstone Medical, the company aims to lead the global market in non-invasive diagnostics for cancer, infectious, and inflammatory diseases, with a focus on breath-based diagnostic tools.

Sibel Health, established in 2018 and headquartered in Evanston, Illinois, specializes in advanced monitoring solutions for healthcare. The company develops soft, flexible sensors that provide clinical-grade, wireless vital signs monitoring, including heart rate, respiratory rate, skin temperature, body position, and activities. These sensors are designed for use on patients and pregnant mothers, offering a comprehensive physiological monitoring platform with advanced analytics for both clinical care and research applications. Sibel Health's innovative digital health solutions are tailored for the pharmaceutical and clinical research sectors, enhancing healthcare delivery and patient outcomes.

Corner Therapeutics is a biotechnology research company focused on immunotherapy. It specializes in developing technologies that stimulate exceptional memory T cells to achieve lifelong immunity. The company utilizes a versatile dendritic cell hyperactivation platform that induces strong T-cell responses, aiming to provide robust and durable immunity against a wide range of cancers and infectious diseases. By enhancing T-cell activation, Corner Therapeutics seeks to enable healthcare providers to promote lasting immunity and optimize immune regulation.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

Brightseed, Inc. is a biotechnology company based in San Francisco, California, that specializes in the discovery of bioactive compounds in plants to enhance human health. Utilizing its advanced Forager platform, which employs artificial intelligence and machine learning algorithms, Brightseed accelerates the identification and validation of clinically beneficial molecules. This innovative approach enables the company to uncover connections between natural compounds and health outcomes, revealing the potential of bioactives that have previously remained uncharted. By integrating these discoveries back into the food supply chain, Brightseed collaborates with various companies across the consumer health continuum to develop science-backed health solutions aimed at managing chronic diseases and improving overall quality of life. Founded in 2017, Brightseed is committed to exploring the untapped resources of the plant kingdom to address pressing health challenges.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

VitriVax is a biotechnology startup based in Boulder, Colorado, focused on developing an innovative vaccine formulation platform. The company utilizes its proprietary atomic layering thermostable antigen and adjuvant (ALTA) technology to create vaccines that are more effective, affordable, and accessible worldwide. This technology addresses the challenges associated with vaccine stability and administration by enabling the development of thermostable, single-shot vaccines that can effectively incorporate both prime and booster doses. VitriVax's advancements in vaccine formulation aim to eliminate barriers to global vaccination, ultimately enhancing immune responses for a broad range of medical indications. The company has received significant funding, including over $5 million from various sources such as the National Institutes of Health, the National Science Foundation, and the Bill and Melinda Gates Foundation, to support its mission.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

BiomEdit is an innovation company focused on developing novel probiotics and microbiome-derived bioactives to enhance animal health. The company aims to tackle significant challenges in animal agriculture and food security by harnessing the potential of the microbiome. Utilizing a unique platform that incorporates high-throughput sequencing and data analytics, BiomEdit rapidly discovers and screens new probiotic species and bioactive molecules. These innovations can be engineered for improved thermostability, increased production of beneficial metabolites, and expression of immune-modulating proteins. By creating next-generation products that promote animal health without relying on antibiotics, BiomEdit addresses critical needs in livestock production and disease management.

Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.

GE Healthcare is a multinational healthcare company based in Chicago, Illinois, that specializes in manufacturing a diverse range of medical equipment and technologies. Founded in 1892, the company offers products and services including medical imaging, information technologies, medical diagnostics, and patient monitoring systems. GE Healthcare also supports drug discovery and biopharmaceutical manufacturing through intelligent devices and data analytics. The company aims to enhance patient care and outcomes by providing innovative healthcare solutions utilized in hospitals, clinics, research institutions, and pharmaceutical companies globally. By focusing on precision health and digitizing healthcare, GE Healthcare seeks to improve productivity and health outcomes for patients and healthcare providers alike. Additionally, the company pursues an aggressive acquisition strategy to strengthen its presence in emerging markets and expand its life sciences portfolio.

The American University of Beirut (AUB), established in 1866 and formerly known as Syrian Protestant College, is a prominent educational institution located in Beirut, Lebanon. Adhering to the American liberal arts model, AUB emphasizes a teaching-centered approach to research and education. It offers over 120 academic programs across six faculties: Agricultural and Food Sciences, Arts and Sciences, Engineering and Architecture, Health Sciences, Medicine, and Business Management. The university serves approximately 8,000 students, supported by around 800 instructional faculty, with a balanced gender ratio of 50 percent male and 50 percent female. AUB fosters an environment that encourages freedom of thought and expression, aiming to cultivate graduates equipped with critical thinking skills, personal integrity, and civic responsibility. The institution is accredited by the Commission on Higher Education of the Middle States Association of Colleges and Schools in the United States, having received its initial accreditation in 2004. Instruction is primarily conducted in English, except for specific language courses.

EHA Clinics is dedicated to providing accessible, effective, and affordable healthcare services. The organization offers a comprehensive healthcare network that includes routine medical care, laboratory services, pharmacy, optometry, dental care, urgent care, and specialist consultations. EHA Clinics ensures that members have round-the-clock access to healthcare through various channels, including physical locations, telehealth virtual visits, and home care services. By leveraging technology and a skilled team, EHA Clinics aims to enhance the healthcare experience, improve patient outcomes, and offer competitive pricing for individual, family, and business members.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

Latham BioPharm Group (LBG) specializes in providing comprehensive support for the life sciences sector, focusing on advancing programs through a range of services that include business development, program management, quality assurance, regulatory guidance, and strategic consulting. With a team averaging over 20 years of experience, many of whom have held senior positions in both private enterprises and the US government, LBG has a proven track record in biodefense, pandemic response, and product development. Over the past two decades, the firm has successfully helped clients secure more than $1 billion in government funding and over $100 million in licensing fees. Their services encompass critical business evaluations, market assessments, and assistance in obtaining funding, followed by effective program management to drive projects toward key milestones. By integrating expertise in vaccine, therapeutic, medical device, and diagnostic product development, LBG aids clients in achieving their organizational objectives efficiently and effectively.

Aegis Life is a biotechnology company focused on advancing nucleic acid delivery technology, specifically through its proprietary platform known as fusogenix PLV. This technology, developed over two decades, is designed to facilitate the rapid development and commercialization of vaccines and therapeutics aimed at preventing and treating infectious diseases. Aegis Life's innovative approach supports the pharmaceutical industry in accelerating the discovery, clinical development, and manufacturing processes for vaccines and treatments, particularly in response to emerging health threats such as COVID-19.

Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Founded in 2014, Kallyope employs a multidisciplinary approach, integrating technologies such as sequencing, computational biology, neural imaging, and human genetics to deepen the understanding of gut-brain biology. This comprehensive understanding enables the company to create effective and well-tolerated oral medications targeting various health issues, including diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies. With a team of experienced scientists and a strong foundation in drug discovery, Kallyope aims to address significant unmet medical needs through its research and development efforts.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Audere is a digital health nonprofit developing software to improve global health in underserved communities.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Noze is a leader in digital odor perception technology, creating advanced solutions that replicate the human sense of smell. Their sophisticated digital nose utilizes a specialized sensor, developed with NASA technology, to detect and identify odors in various real-world environments. This technology collects and analyzes data through an AI engine, allowing healthcare providers to assess air quality, monitor chemical footprints, and potentially diagnose diseases based on breath-based odor biomarkers. By enabling real-time disease detection and routine health screenings with a single exhale, Noze aims to enhance human health and well-being while improving patient outcomes.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Aspen Pharmacare Holdings Limited is a global specialty pharmaceutical company headquartered in Durban, South Africa. It manufactures and supplies a diverse portfolio of specialty, branded, and generic pharmaceutical products across more than 150 countries. The company operates through two main segments: Commercial Pharmaceuticals and Manufacturing. Aspen offers a range of products, including general anaesthetics, muscle relaxants, cytotoxic medicines, and injectable anticoagulants, with a focus on low molecular weight heparins. Additionally, Aspen engages in the contract manufacturing and supply of active pharmaceutical ingredients and finished dose pharmaceuticals for third parties. The company's extensive product offerings include oral solids, injectables, liquids, semi-solids, and biologicals. With a strong presence in various international markets, including Africa, Asia, Europe, and the Americas, Aspen continues to expand its operations through strategic acquisitions and partnerships. Founded in 1850, Aspen has established itself as a leading player in the pharmaceutical industry.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Touchlight Genetics Ltd. is a biotechnology company based in Leatherhead, United Kingdom, specializing in DNA therapies and technology. Founded in 2007, it has developed the proTL synthetic DNA platform, which allows for the production of doggybone closed linear DNA without the need for bacterial fermentation. This innovative approach supports various applications, including veterinary vaccines, monoclonal antibodies, cancer and gene therapies, allergy treatments, RNA interference therapies, and stem cell reprogramming. The company boasts a skilled scientific and drug development team, led by founder and CEO Jonny Ohlson, and includes experienced professionals such as Clive Dix and John Tite. Touchlight has established partnerships with several leading academic institutions, including Imperial College London and the University of Pennsylvania, to advance its research and development efforts. The company has successfully patented its synthetic DNA platform and demonstrated therapeutic proof-of-principle through collaboration with these academic partners.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Contro is an online service that specializes in the prescription and delivery of sexual health and confidence products, including birth control and erectile dysfunction treatments. Through its secure digital platform, Contro enables individuals to manage their personal wellness conveniently and affordably. The service offers one-off digital consultations with licensed doctors, who prescribe the necessary medications during the consultation. These prescriptions are then delivered discreetly to customers' doors on a monthly basis, with the flexibility to cancel the subscription at any time. By prioritizing privacy and accessibility, Contro aims to empower individuals in South Africa to take control of their sexual health.

Bayer is a multinational corporation with a focus on life science industries. It operates in three main business areas: Pharmaceuticals, Consumer Health, and Crop Science. Bayer Pharmaceuticals develops and markets a wide range of medicines, including those for cardiovascular diseases, oncology, and women's health. The Consumer Health division offers over-the-counter products and medical devices, while Crop Science provides crop protection products, seeds, and digital farming solutions. Bayer Animal Health, a part of the Crop Science division, is a global leader in animal health, offering a broad portfolio of products for the treatment and prevention of diseases in livestock and companion animals. The company's global presence and extensive product portfolio enable it to address various health challenges in humans, animals, and crops, contributing to a sustainable future.

Helium Health is a technology company focused on transforming healthcare in Africa by providing a comprehensive suite of software solutions for hospitals and clinics. The company specializes in electronic health record systems that facilitate the management of patient data and hospital operations. Its platform simplifies various processes, including doctor visits, prescriptions, and medical billing, making it accessible from any device. Additionally, Helium Health offers customizable forms and tools for monitoring healthcare trends, generating alerts, and producing reports. By leveraging technology, the company aims to create a modern and affordable healthcare system while aspiring to become the largest healthcare data exchange in Africa.

CQUIN is made up of representatives from ministries of health, implementing partners, civil society, associations of people living with HIV, academic institutions, and donor agencies that work with CQUIN to scale up DSD according to each country’s unique needs. The company encourages experience sharing, peer-to-peer learning, and collaborative issue solving. It allows member countries to obtain technical support from Columbia University's ICAP.

Bactolife is a company dedicated to addressing the global challenge of antimicrobial resistance through innovative solutions. Its proprietary Binding Protein ingredients are designed to strengthen the gut microbiome and minimize the risk of gastrointestinal infections in both humans and animals. By focusing on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, Bactolife aims to enhance gut health and reduce reliance on traditional antimicrobials. The company's approach emphasizes the modulation of the gut microbiome to improve overall health outcomes, making a significant contribution to the fight against antimicrobial resistance. Through its developments, Bactolife seeks to empower individuals and communities worldwide in maintaining better health.

CaliberMRI is a platform that includes brain, breast, prostate, and custom phantoms, and companion automated quality control software. They provide services that include quantitative MRI, qmri, phantoms, quantitative medicine, radiology, breast cancer, and calibration.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Iconovo AB, based in Lund, Sweden, specializes in developing and licensing inhalation devices. It offers a range of dry powder inhalers, including ICOres, ICOcap, ICOone, and ICOpre, catering to generic pharmaceutical companies. With a focus on technical innovation, user-friendly design, and cost-efficiency, Iconovo aims to become a global leader in its field, targeting a multimillion turnover within five years.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Yemaachi Biotechnology is focused on advancing the diagnosis and treatment of cancer through innovative therapeutic technologies. The company employs immunogenomics, bioinformatics, and artificial intelligence to enhance the development of effective cancer detection and treatment strategies. By leveraging these advanced methodologies, Yemaachi aims to lower the economic burden of cancer and improve patient outcomes through more accurate and efficient therapeutic solutions.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2015. The company specializes in the development and production of messenger ribonucleic acid (mRNA) vaccines formulated in lipid nanoparticles. Its portfolio includes PTX-101, a personalized mRNA cancer vaccine aimed at treating advanced ovarian cancer, and various COVID-19 vaccines, including PTX-COVID19-B and PTX-COVID19-T, which target the coronavirus and elicit immune responses against the virus. Providence Therapeutics is committed to creating safe and effective therapies to address unmet medical needs, particularly in oncology and infectious diseases, thereby enhancing the quality of life for patients.

MyDawa is an online pharmacy that provides a convenient platform for individuals to purchase a wide range of high-quality medications and wellness products directly from their mobile devices. By connecting patients to drug stores, MyDawa facilitates affordable access to essential medications without imposing service fees, transaction charges, or delivery costs. This approach aims to streamline the pharmaceutical supply chain, addressing common challenges faced by consumers when sourcing health-related products. MyDawa’s innovative service offers a straightforward and efficient solution for obtaining necessary health items, thereby enhancing the overall customer experience in the healthcare sector.

Philips, established in 1891, is a Dutch diversified technology company that focuses on improving people's health and well-being through meaningful innovation. The company operates in three segments: Diagnosis & Treatment, Connected Care, and Personal Health. Philips Healthcare, a division of Philips, is a leader in diagnostic imaging, image-guided therapy, patient monitoring, health informatics, consumer health, and home care. It offers a wide range of products such as CT scanners, MRI machines, ultrasound equipment, and more, aiming to enhance preventive care, diagnosis, and treatment. Additionally, Philips Research drives innovation across these segments, while the Philips Foundation focuses on reducing healthcare inequality through access to quality care for disadvantaged communities. The company also provides lighting solutions and consumer lifestyle products, including personal care and oral healthcare items.

Inventprise is a biotechnology company based in Redmond, Washington, focused on developing vaccines to combat infectious diseases. Established in 2012, the company is known for its 25-valent pneumococcal conjugate vaccine (PCV), which is supported by significant funding from the Bill and Melinda Gates Foundation, exceeding $100 million. This vaccine is specifically designed for large-scale distribution in low- and middle-income countries. In addition to vaccine development, Inventprise offers comprehensive contract manufacturing and development services, including quality control assays, batch records, and training. The company also operates a fully equipped quality control laboratory that conducts testing for identity, potency, purity, and stability, thereby assisting clients in addressing health disparities and promoting public health.

Brightseed, Inc. is a biotechnology company based in San Francisco, California, that specializes in the discovery of bioactive compounds in plants to enhance human health. Utilizing its advanced Forager platform, which employs artificial intelligence and machine learning algorithms, Brightseed accelerates the identification and validation of clinically beneficial molecules. This innovative approach enables the company to uncover connections between natural compounds and health outcomes, revealing the potential of bioactives that have previously remained uncharted. By integrating these discoveries back into the food supply chain, Brightseed collaborates with various companies across the consumer health continuum to develop science-backed health solutions aimed at managing chronic diseases and improving overall quality of life. Founded in 2017, Brightseed is committed to exploring the untapped resources of the plant kingdom to address pressing health challenges.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases through its innovative ProNeura long-term drug delivery platform. The company's key product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed to provide stable medication levels for up to six months, thereby enhancing patient compliance in the treatment of opioid dependence. Titan also develops ProNeura-Ropinirole, an implant for delivering ropinirole to treat Parkinson's disease, and a similar implant for managing hypothyroidism. The ProNeura technology holds promise for addressing various chronic conditions by ensuring consistent drug delivery, which can improve patient outcomes. In December 2012, Titan entered a licensing agreement granting Braeburn Pharmaceuticals exclusive commercialization rights to Probuphine in the U.S. and Canada, receiving significant financial incentives tied to regulatory approvals and sales milestones. Additionally, Titan receives royalties from the sales of Fanapt, an atypical antipsychotic, further supporting its development efforts.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Sunflower Therapeutics is a biotechnology company focused on advancing protein manufacturing solutions to enhance global access to biological medicines. By employing strain engineering and integrated process development, the company aims to create efficient, automated systems for protein production. These innovations are designed to support a wide range of applications, including new medicines and food products, allowing clients to significantly reduce the time and costs associated with developing and manufacturing biologics. Sunflower Therapeutics emphasizes values such as wellness, integrity, ethics, equity, community, and efficiency in its operations, reflecting its commitment to benefiting the global population.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on enhancing healthcare access in rural Africa by developing and distributing AI-powered diagnostic devices. These compact devices are designed for primary care doctors in peri-urban and rural clinics, providing accurate and affordable diagnostic services. Ilara Health integrates its technology within a proprietary platform that connects to an electronic medical record system, allowing healthcare providers to efficiently record and manage patient data. By leveraging existing healthcare infrastructure, Ilara Health aims to improve the accessibility and affordability of diagnostic services in underserved regions.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.

Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.

Particles for Humanity is focused on developing early-stage medical technologies aimed at enhancing the quality of life for individuals in low-resource settings. The organization formulates a portfolio of healthcare products designed to improve vaccination rates and combat malnutrition. By incorporating end-user input into its rigorous product development process, Particles for Humanity seeks to create financially sustainable solutions that address serious medical challenges faced by these communities.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines aimed at treating, curing, and protecting individuals from diseases related to human papillomavirus (HPV), cancer, and infectious diseases. The company's innovative SynCon immunotherapy design enables the immune system to target cancerous cells while providing cross-strain protection against various pathogens. Inovio's clinical studies focus on HPV-associated precancers, cancers, and other disorders, as well as diseases such as glioblastoma multiforme, HIV, and COVID-19. The company has developed a proprietary delivery system that allows DNA medicine to be introduced directly into cells, producing a strong immune response. Notably, its lead candidate, VGX-3100, is undergoing Phase 3 trials for precancerous cervical dysplasia, having shown promise in earlier trials by effectively clearing high-risk HPV strains. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio collaborates with various partners, including major pharmaceutical companies and research institutions, to advance its clinical initiatives and expand its therapeutic reach.

Centre for Innovation in Regulatory Science is a neutral, independently managed UK-based subsidiary company, forming part of the Clarivate Analytics group. CIRS provides an international forum for industry, regulators, HTA and other healthcare stakeholders to meet, debate and develop regulatory and reimbursement policy through the innovative application of regulatory science and to facilitate access to medical products. This is CIRS’ purpose. CIRS is operated solely for promotion of its purpose. The organisation has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities, special projects and grants.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Biological Dynamics Inc. is a healthcare company based in San Diego, California, focused on enhancing global health outcomes through early disease detection. The company has developed a proprietary technology platform that enables the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This platform facilitates the analysis of native-state biomarkers and nanoparticles, supporting multiomics applications. Biological Dynamics specializes in cancer detection and offers a range of services, including the TR(ACE) Assay for monitoring treatment responses and tumor burdens, as well as liquid biopsy testing for personalized medicine. Additionally, the company provides clinical laboratory services, including molecular and next-generation sequencing, and has programs aimed at drug development in areas such as Alzheimer's disease. Founded in 2008, Biological Dynamics is committed to utilizing machine learning and its advanced technology to address various health challenges, including autoimmune diseases, transplant rejection, and traumatic brain injury.

VisualDx is a clinical decision support system that aims to improve diagnostic accuracy and patient safety in healthcare settings. By integrating a curated medical image library with a robust search engine, it provides clinicians with patient-specific answers swiftly, facilitating informed therapeutic decisions. The platform encompasses high-quality images covering a range of both pediatric and adult medical conditions. Used by over 2,300 hospitals, clinics, and medical schools globally, VisualDx enhances point-of-care decisions and fosters better patient engagement, enabling healthcare providers to deliver timely and effective care.

1mg is an Indian digital healthcare platform, launched in 2015, that operates from Gurgaon, Haryana. It aims to make healthcare more accessible, understandable, and affordable. The platform enables users to find detailed information about prescribed medicines, buy them, and search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a doctor platform to help users find suitable healthcare professionals and a diagnostics service for transparent and cost-effective lab tests. The company empowers consumers and caregivers to choose the most appropriate healthcare services at competitive prices.

Almac Group is a contract development and manufacturing organization that provides a comprehensive range of services to pharmaceutical and biotech companies worldwide. Established over 40 years ago and privately owned, the company specializes in research and development, biomarker discovery, active pharmaceutical ingredient (API) manufacturing, formulation development, clinical trial supply, and companion diagnostic development. Headquartered in Craigavon, Northern Ireland, Almac operates additional facilities in the UK, Ireland, the US, and Asia. With a workforce exceeding 4,500 employees, the company is committed to continuous investment in its service offerings, including advancements in biomarker and companion diagnostics, clinical trial data management, and biocatalytic API manufacturing. Almac Discovery, a division of the group, is dedicated to the research and development of innovative cancer treatments, focusing on early-stage partnerships for further program development.

Landcent is a company dedicated to combating global infectious diseases, with a focus on malaria. It develops and delivers affordable, sustainable solutions that are safe for large-scale use, aiming to accelerate the fight against these diseases and ultimately eliminate them.

RJH Biosciences is a biotechnology company specializing in the development of transfection reagents and delivery systems designed to transport various types of nucleic acids into human cells and cell lines. The company emphasizes innovative solutions for addressing blood cancers and modifying immune cells, thereby enhancing the therapeutic potential of nucleic acids in medical applications. RJH Biosciences distributes its products through its website and is also engaged in projects aimed at developing new medical treatments.

One.bio is a biotechnology spinout from UC Davis that specializes in developing naturally-derived oligosaccharides for applications in food, agriculture, and biopharmaceuticals. Utilizing proprietary technology, the company creates innovative ingredients aimed at modulating the microbiome and enhancing immune function. This focus allows One.bio to provide clients with access to novel prebiotics and therapies that support both human and animal health. By unlocking the benefits of nutrition, One.bio aims to contribute to improved longevity and overall well-being.

Credence MedSystems, Inc. is a drug delivery and specialty pharmaceutical company based in Menlo Park, California, focused on enhancing the safety of injectable medications for patients and caregivers. The company develops innovative products, including the Companion Staked Needle Syringe, Companion Luer Syringe, and the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable mechanism for safer use. Credence MedSystems aims to simplify the commercialization process for pharmaceutical partners by integrating advanced safety features into existing drug delivery systems without necessitating significant changes to their manufacturing processes. This approach, termed "Innovation Without Change," allows for a more efficient path to market while ensuring that the delivery systems meet high standards of safety and efficacy. The company, formerly known as SafeShot Technologies, Inc., was established in 2011 and has formed a strategic collaboration with SCHOTT AG to further enhance its product offerings.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, the company focuses on creating orally administered dosage forms that can deliver a sustained release of medications for periods ranging from a week to a month while remaining in the stomach. Lyndra's therapeutic initiatives target a variety of conditions, including Alzheimer's disease, cardiovascular and metabolic disorders, psychiatric issues, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By enhancing medication adherence and improving health outcomes, Lyndra Therapeutics aims to contribute to lower healthcare costs and better patient care.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, making healthcare more accessible. The platform also allows patients to order laboratory tests that can be conducted at home. Additionally, HaloDoc helps users locate the nearest hospitals and clinics, streamlining the process of obtaining medical advice and services in real-time.